MA45186A - Domaines de fibronectine de type iii se liant à l'albumine sérique - Google Patents

Domaines de fibronectine de type iii se liant à l'albumine sérique

Info

Publication number
MA45186A
MA45186A MA045186A MA45186A MA45186A MA 45186 A MA45186 A MA 45186A MA 045186 A MA045186 A MA 045186A MA 45186 A MA45186 A MA 45186A MA 45186 A MA45186 A MA 45186A
Authority
MA
Morocco
Prior art keywords
areas
type iii
fibronectin binding
iii fibronectin
seric albumin
Prior art date
Application number
MA045186A
Other languages
English (en)
Inventor
Michael Diem
Steven Jacobs
Karyn O'neil
Thomas Rutkoski
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA45186A publication Critical patent/MA45186A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045186A 2016-06-03 2017-06-01 Domaines de fibronectine de type iii se liant à l'albumine sérique MA45186A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345190P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
MA45186A true MA45186A (fr) 2019-04-10

Family

ID=60477987

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045186A MA45186A (fr) 2016-06-03 2017-06-01 Domaines de fibronectine de type iii se liant à l'albumine sérique

Country Status (13)

Country Link
US (3) US10925932B2 (fr)
EP (1) EP3463430B1 (fr)
JP (2) JP7111627B2 (fr)
KR (1) KR102461666B1 (fr)
CN (1) CN109562146A (fr)
AU (1) AU2017273743B2 (fr)
EA (1) EA201892796A1 (fr)
IL (2) IL263347B (fr)
MA (1) MA45186A (fr)
MX (1) MX2018014876A (fr)
SG (1) SG11201810687SA (fr)
UA (1) UA126021C2 (fr)
WO (1) WO2017210425A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
SG11201810687SA (en) * 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
MA45412A (fr) * 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
EP3554535A4 (fr) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à pd-l1
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (fr) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
CN110724198B (zh) * 2018-07-17 2023-05-26 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (fr) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Domaines de type iii de fibronectine de liaison à cd137
CN115175691B (zh) * 2019-12-18 2026-02-10 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用
CA3214552A1 (fr) 2021-04-14 2022-10-20 Russell C. Addis Domaines fibronectine de type iii de liaison a cd71
EP4323008A4 (fr) 2021-04-14 2026-02-25 Aro Biotherapeutics Company Conjugués domaine fn3-arnsi et leurs utilisations
USD1021702S1 (en) * 2021-10-20 2024-04-09 GM Global Technology Operations LLC Vehicle center grille
WO2025073871A1 (fr) 2023-10-03 2025-04-10 Bicycletx Limited Complexes de ligands peptidiques bicycliques spécifiques de tfr1

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
EP1958962A3 (fr) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Polypeptides anticorps artificiels
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1240337B1 (fr) 1999-12-24 2006-08-23 Genentech, Inc. Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DK1534830T3 (da) 2002-09-06 2011-02-14 Isogenica Ltd In vito-peptid-ekspressionsbibliotek
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2009085468A2 (fr) 2007-12-19 2009-07-09 Centocor, Inc. Vecteurs de phages de synthèse destinés à la conception et à la génération d'une banque de phages protéines ou peptides non anticorps humains par fusion au pix du phage m13
EA201001734A1 (ru) * 2008-05-02 2011-10-31 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
ES2705714T3 (es) * 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
BRPI1008532B1 (pt) * 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
JP6440496B2 (ja) 2011-09-27 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA2932819A1 (fr) * 2013-12-09 2015-06-18 New York University Compositions et methodes utilisees pour administrer des agents anti-staphylococciques par phagocytose
ES2736127T3 (es) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
SG11201810687SA (en) 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
MA45412A (fr) * 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine

Also Published As

Publication number Publication date
UA126021C2 (uk) 2022-08-03
JP2022046510A (ja) 2022-03-23
SG11201810687SA (en) 2018-12-28
KR102461666B1 (ko) 2022-11-01
IL282960A (en) 2021-06-30
US20170348397A1 (en) 2017-12-07
EA201892796A1 (ru) 2019-06-28
US12599652B2 (en) 2026-04-14
EP3463430A4 (fr) 2020-02-12
JP7111627B2 (ja) 2022-08-02
US20210228688A1 (en) 2021-07-29
IL263347B (en) 2021-05-31
JP2019521662A (ja) 2019-08-08
EP3463430B1 (fr) 2025-01-01
AU2017273743A1 (en) 2019-01-03
MX2018014876A (es) 2019-05-22
US20240100129A1 (en) 2024-03-28
AU2017273743B2 (en) 2021-12-02
IL263347A (en) 2018-12-31
US11833190B2 (en) 2023-12-05
EP3463430A1 (fr) 2019-04-10
KR20190013970A (ko) 2019-02-11
IL282960B (en) 2022-03-01
CN109562146A (zh) 2019-04-02
WO2017210425A1 (fr) 2017-12-07
US10925932B2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
EP3463430A4 (fr) Domaines de fibronectine de type iii se liant à l'albumine sérique
IL295358A (en) Using programmable dna binding proteins to enhance targeted genome modification
EP3461261A4 (fr) Protéines se liant au fragment monocaténaire variable de cd3
MA51734A (fr) Anticorps se liant à gprc5d
EP3408400A4 (fr) Protéines de liaison à l'antigène se liant à pd-l1
MA45680A (fr) Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
EP3695666C0 (fr) Détection d'actions de conduite qui atténuent le risque
MA51649A (fr) Culture de placenta pour isoler des exosomes
MA46893A (fr) Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
EP2834260A4 (fr) Polynucléotides modifiés pour la production de protéines membranaires
EP2855509A4 (fr) Domaines consensus non endogènes de liaison à l'albumine
MA42060A (fr) Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate
MA42377A (fr) Anticorps se liant à tau
EP3393608A4 (fr) Solutions planaires à des problèmes de suivi d'objet
EP3578165A4 (fr) Produit cosmétique de correction d'irrégularités
MA43660A (fr) Anticorps anti-facteur xi de coagulation
MA56416A (fr) Détermination de la pureté de protéines multimériques
EP3672600A4 (fr) Composition synthétique pour réduire les symptômes d'allergie
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA45234A (fr) Anticorps anti-facteur xi de coagulation
EP3297662A4 (fr) Anticorps se liant à des protéines axl
EP3845644C0 (fr) Nouveau mutant d'albumine sérique humaine
EP3436049A4 (fr) Protéine 8 de type angiopoïétine (angptl8)
EP3689903A4 (fr) Protéine se liant au domaine de la fibronectine b
EP3414517A4 (fr) Caractérisation holographique d'agrégats de protéines